The Gynecologic Oncology Group
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1970-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.gog.org
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
- Conditions
- Cervical AdenocarcinomaCervical Adenosquamous CarcinomaCervical Squamous Cell Carcinoma, Not Otherwise SpecifiedPersistent DiseaseRecurrent Cervical Carcinoma
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2010-12-28
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 31
- Registration Number
- NCT01267253
- Locations
- 🇺🇸
Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States
🇺🇸Beebe Medical Center, Lewes, Delaware, United States
🇺🇸Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States
Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer
- Conditions
- Recurrent Cervical CarcinomaCervical Squamous Cell Carcinoma, Not Otherwise SpecifiedCervical AdenocarcinomaCervical Adenosquamous Carcinoma
- Interventions
- Biological: Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001Other: Laboratory Biomarker Analysis
- First Posted Date
- 2010-12-24
- Last Posted Date
- 2020-09-11
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 54
- Registration Number
- NCT01266460
- Locations
- 🇺🇸
Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
- Conditions
- Endometrial Undifferentiated CarcinomaEndometrial AdenocarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Serous AdenocarcinomaEndometrial Transitional Cell CarcinomaEndometrial Squamous Cell CarcinomaMalignant Uterine Corpus Mixed Epithelial and Mesenchymal NeoplasmEndometrial Mucinous AdenocarcinomaRecurrent Uterine Corpus Carcinoma
- Interventions
- First Posted Date
- 2010-10-21
- Last Posted Date
- 2017-10-09
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 37
- Registration Number
- NCT01225887
- Locations
- 🇺🇸
MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore, Maryland, United States
🇺🇸Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸Bay Area Medical Center, Marinette, Wisconsin, United States
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
- Conditions
- Endometrial AdenocarcinomaEndometrial Endometrioid Adenocarcinoma, Variant With Squamous DifferentiationEndometrioid Stromal SarcomaEndometrial Serous AdenocarcinomaEndometrial Adenosquamous CarcinomaEndometrial Clear Cell AdenocarcinomaRecurrent Uterine Corpus Carcinoma
- Interventions
- Biological: Trebananib
- First Posted Date
- 2010-09-28
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 35
- Registration Number
- NCT01210222
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Hartford Hospital, Hartford, Connecticut, United States
🇺🇸The Hospital of Central Connecticut, New Britain, Connecticut, United States
Prognostic Biomarkers in Patients With Endometrial Cancer
- Conditions
- Stage II Uterine Corpus CancerStage IV Uterine Corpus CancerStage I Uterine Corpus CancerStage III Uterine Corpus CancerRecurrent Uterine Corpus CarcinomaEndometrial Adenocarcinoma
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2010-09-24
- Last Posted Date
- 2017-08-23
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 2824
- Registration Number
- NCT01208467
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Biomarkers in Samples From Patients With Endometrial Cancer
- Conditions
- Stage II Uterine Corpus CancerStage III Uterine Corpus CancerLynch SyndromeRecurrent Uterine Corpus CarcinomaStage IV Uterine Corpus CancerStage I Uterine Corpus Cancer
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2010-09-10
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT01199250
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Racial and Genetic Biomarkers of Response in Tissue Samples From Patients With Endometrial Cancer
- Conditions
- Stage I Uterine Corpus CancerStage II Uterine Corpus CancerStage IV Uterine Corpus CancerStage III Uterine Corpus Cancer
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Study of Socioeconomic and Demographic Variables
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 243
- Registration Number
- NCT01198171
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
- Conditions
- Stage III Uterine Corpus CancerRecurrent Uterine Corpus CarcinomaStage IV Uterine Corpus Cancer
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2010-07-19
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 169
- Registration Number
- NCT01164735
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Role of Biomarkers in Endometrial Cancer Recurrence in Samples From Patients With Stage II, Stage III, or Stage IV Endometrial Cancer
- Conditions
- Endometrial Cancer
- First Posted Date
- 2010-06-25
- Last Posted Date
- 2011-04-29
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 865
- Registration Number
- NCT01150682
Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer
- Conditions
- Fallopian Tube CarcinomaPrimary Peritoneal CarcinomaOvarian NeoplasmBreast Carcinoma
- Interventions
- Procedure: Evaluation of Cancer Risk FactorsOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationProcedure: Study of High Risk Factors
- First Posted Date
- 2010-06-09
- Last Posted Date
- 2020-09-02
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 1916
- Registration Number
- NCT01139957
- Locations
- 🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸University of Cincinnati/Barrett Cancer Center, Cincinnati, Ohio, United States